Avidity Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 253
- Market Cap
- $5.1B
- Introduction
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
AI-Designed DNA Switches Flips Gene Expression On and Off
Researchers used AI to design new DNA switches, called synthetic cis-regulatory elements (CREs), that precisely control gene expression in specific cell types, outperforming naturally occurring CREs in cell-type specificity.
RNAscence can expand RNA patch tech to tackle eczema, hyperpigmentation
Singapore's RNAscence Biotechnology created a dissolvable hyaluronic acid microneedle patch, BioRNA Anti-Scar, delivering RNA to reduce scar appearance. Clinically proven to reduce scar volume by up to 95% in 60 days, it's effective on new and old scars, including keloids. Developed over six years, it's safe and available online and in clinics, with future potential for treating other skin conditions.
Tasmanian tiger poised for incredible comeback after massive breakthrough
Colossal Biosciences made progress in de-extinction of Tasmanian tiger, creating most complete ancient genome, achieving genetic edits, and developing reproductive technologies, bringing thylacine reintroduction to Tasmania closer.
Shape Therapeutics introduces advances in AI-powered platform for precision RNA editing
Shape Therapeutics' RNAfix platform uses engineered gRNAs delivered by AAV to recruit ADAR enzyme for RNA editing, overcoming previous challenges. The DeepREAD AI model and U7 SmOPT expression system enhance RNA editing efficiency and specificity, enabling precise editing of any target adenosine and high gRNA expression in cells, paving the way for treating genetic disorders.
Your guide to the 2024 RANZCO Congress
The 55th RANZCO Congress in Adelaide, 1-4 November 2024, features a dynamic speaker lineup addressing eye transplant feasibility, uveitis insights, and sustainability. Early registrations are up 10% from last year, promising a vibrant event. Key speakers include Prof. Justine Smith on uveitis, Prof. Robyn Jamieson on precision medicine, and Prof. Jeffrey Goldberg on eye transplantation. The congress emphasizes sustainability and offers both in-person and online experiences.
5 FDA Decisions to Watch in Q4 2024
Highly anticipated FDA approvals by year-end include acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for type 1 diabetes, oral sulopenem for uUTI, and DFD-29 for rosacea.
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology
QIAGEN launches QIAcuityDx Digital PCR System, expanding into clinical diagnostics with 510(k) exemption in the U.S. and IVDR certification in Europe. The system offers precise DNA and RNA quantification, supporting cancer monitoring and complementing NGS. QIAGEN plans to submit a BCR::ABL assay for FDA approval in 2025 and has partnered with pharmaceutical companies for companion diagnostics. The platform integrates partitioning, thermocycling, and imaging, reducing lab space and operator time, and includes user-friendly software with IVD and Utility modes.
Second generation of I-SPY 2 TRIAL design is driving the “precise” in precision medicine
Quantum Leap Healthcare Collaborative's I-SPY 2.2 trial aims to personalize treatment for high-risk early-stage breast cancer patients, potentially preventing recurrence and improving outcomes. The trial's adaptive design allows for treatment optimization based on individual responses, accelerating drug development and delivery for various diseases.
Alloy Therapeutics Introduces New Licensing Model for ATX-Gx Antibody Technology, Collaborates with Sanofi and Takeda to Revolutionize Therapeutic Development
Alloy Therapeutics introduces a new licensing model for its ATX-Gx antibody technology, eliminating annual fees and milestones, enhancing drug discovery. Collaborates with Sanofi on AntiClastic Antisense Platform for CNS targets and with Takeda on iPSC-derived CAR-T/NK platforms, aiming to revolutionize therapeutic development.
Key Drug Discovery Patents from August 2023 to November 2024
The article covers key drug discovery patents from August 2023 to November 2024, highlighting innovations like Amgen’s 15-PGDH inhibitors, brain-penetrant CD38 inhibitors, and next-generation CRM1 inhibitors. It also mentions PIP4K2C inhibitors, POLRMT inhibitors, and MAPT pre-mRNA splicing modulators for cancer and tauopathy treatments. The Drug Hunter team curated over 200 significant patents monthly, providing detailed annotations for each to streamline the review process.
© Copyright 2025. All Rights Reserved by MedPath